Concerns over pharma FDI, M&A arise in India

09/4/2013 | BioSpectrum Asia

India is worried about foreign direct investment in its pharmaceutical industry as multinationals acquire domestic generic drugmakers. Concerns have been raised about off-patent drugs' pricing and availability under multinational ownership, Indian Commerce and Industry Minister Anand Sharma said. The ministry is discussing the possibility of new policies on foreign direct investment related to the country's generic drug industry.

View Full Article in:

BioSpectrum Asia

Published in Briefs: